Literature DB >> 12378272

Use of the post-insertion method for the formation of ligand-coupled liposomes.

Theresa M Allen1, Puja Sapra, Elaine Moase.   

Abstract

A new technique is described for the formation of ligand-targeted liposomes that can be used with whole antibodies, antibody fragments, peptides or other ligands. The ligands are coupled to polyethylene glycol micelles and then transferred in a simple incubation step from the micelles into the outer monolayer of pre-formed, drug-loaded liposomes. This versatile method allows a combinatorial approach to the design of targeted liposomes that minimises manufacturing complexities, allowing a variety of ligands to be inserted into a variety of pre-formed liposomes containing a variety of drugs. This allows the ligand-targeted therapeutics to be tailored to the needs of individual patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378272

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  26 in total

1.  Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer.

Authors:  Swati Biswas; Pranali P Deshpande; Federico Perche; Namita S Dodwadkar; Shailendra D Sane; Vladimir P Torchilin
Journal:  Cancer Lett       Date:  2013-02-16       Impact factor: 8.679

2.  Selective targeting of alveolar type II respiratory epithelial cells by anti-surfactant protein-C antibody-conjugated lipoplexes.

Authors:  Yun Wu; Junyu Ma; Parker S Woods; Nicholas M Chesarino; Chang Liu; L James Lee; Serge P Nana-Sinkam; Ian C Davis
Journal:  J Control Release       Date:  2015-02-14       Impact factor: 9.776

3.  Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.

Authors:  Erez Koren; Anjali Apte; Ankur Jani; Vladimir P Torchilin
Journal:  J Control Release       Date:  2011-12-13       Impact factor: 9.776

4.  Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomes.

Authors:  Shihong Li; Beth Goins; Brian A Hrycushko; William T Phillips; Ande Bao
Journal:  Mol Pharm       Date:  2012-08-23       Impact factor: 4.939

Review 5.  Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.

Authors:  Anu Puri; Kristin Loomis; Brandon Smith; Jae-Ho Lee; Amichai Yavlovich; Eliahu Heldman; Robert Blumenthal
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2009       Impact factor: 4.889

6.  Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.

Authors:  Xiaojuan Yang; Chee Guan Koh; Shujun Liu; Xiaogang Pan; Ramasamy Santhanam; Bo Yu; Yong Peng; Jiuxia Pang; Sharon Golan; Yeshayahu Talmon; Yan Jin; Natarajan Muthusamy; John C Byrd; Kenneth K Chan; L James Lee; Guido Marcucci; Robert J Lee
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

7.  Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.

Authors:  Yingna He; Linhua Zhang; Cunxian Song
Journal:  Int J Nanomedicine       Date:  2010-09-20

8.  Precise quantification of nanoparticle internalization.

Authors:  Claudia Gottstein; Guohui Wu; Benjamin J Wong; Joseph Anthony Zasadzinski
Journal:  ACS Nano       Date:  2013-06-03       Impact factor: 15.881

9.  Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.

Authors:  Swati Biswas; Namita S Dodwadkar; Pranali P Deshpande; Shruti Parab; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2013-01-17       Impact factor: 5.571

10.  Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment.

Authors:  Haimei Chen; Samuel Pazicni; Nancy L Krett; Richard W Ahn; James E Penner-Hahn; Steven T Rosen; Thomas V O'Halloran
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.